Free Trial

Hims & Hers Health (HIMS) Competitors

Hims & Hers Health logo
$19.73 -0.01 (-0.03%)
Closing price 11/13/2026 03:59 PM Eastern
Extended Trading
$19.39 -0.34 (-1.70%)
As of 11/13/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HIMS vs. GH, BTSG, TEM, FMS, and DVA

Should you buy Hims & Hers Health stock or one of its competitors? Hims & Hers Health's main competitors and comparable companies include Guardant Health (GH), BrightSpring Health Services (BTSG), Tempus AI (TEM), Fresenius Medical Care AG & Co. KGaA (FMS), and DaVita (DVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Hims & Hers Health compare to Guardant Health?

Guardant Health (NASDAQ:GH) and Hims & Hers Health (NYSE:HIMS) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Hims & Hers Health has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guardant Health$1.28B16.05-$416.28M-$3.68N/A
Hims & Hers Health$2.35B1.97$128.37M-$0.83N/A

92.6% of Guardant Health shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 5.6% of Guardant Health shares are held by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Guardant Health currently has a consensus price target of $190.88, indicating a potential upside of 25.83%. Hims & Hers Health has a consensus price target of $31.53, indicating a potential upside of 59.86%. Given Hims & Hers Health's higher probable upside, analysts clearly believe Hims & Hers Health is more favorable than Guardant Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Guardant Health
1 Sell rating(s)
0 Hold rating(s)
24 Buy rating(s)
1 Strong Buy rating(s)
2.96
Hims & Hers Health
1 Sell rating(s)
12 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13

In the previous week, Hims & Hers Health had 50 more articles in the media than Guardant Health. MarketBeat recorded 63 mentions for Hims & Hers Health and 13 mentions for Guardant Health. Guardant Health's average media sentiment score of 0.09 beat Hims & Hers Health's score of -0.30 indicating that Guardant Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Guardant Health
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
Hims & Hers Health
2 Very Positive mention(s)
6 Positive mention(s)
22 Neutral mention(s)
25 Negative mention(s)
2 Very Negative mention(s)
Neutral

Guardant Health has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.53, suggesting that its stock price is 153% more volatile than the broader market.

Hims & Hers Health has a net margin of -6.65% compared to Guardant Health's net margin of -37.93%. Guardant Health's return on equity of 0.00% beat Hims & Hers Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Guardant Health-37.93% N/A -25.03%
Hims & Hers Health -6.65%-9.62%-1.38%

Summary

Hims & Hers Health beats Guardant Health on 10 of the 17 factors compared between the two stocks.

How does Hims & Hers Health compare to BrightSpring Health Services?

BrightSpring Health Services (NASDAQ:BTSG) and Hims & Hers Health (NYSE:HIMS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

63.5% of Hims & Hers Health shares are owned by institutional investors. 2.8% of BrightSpring Health Services shares are owned by insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BrightSpring Health Services has a net margin of 2.69% compared to Hims & Hers Health's net margin of -6.65%. BrightSpring Health Services' return on equity of 18.56% beat Hims & Hers Health's return on equity.

Company Net Margins Return on Equity Return on Assets
BrightSpring Health Services2.69% 18.56% 6.03%
Hims & Hers Health -6.65%-9.62%-1.38%

BrightSpring Health Services has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than BrightSpring Health Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BrightSpring Health Services$12.91B1.10$190.67M$1.8538.49
Hims & Hers Health$2.35B1.97$128.37M-$0.83N/A

BrightSpring Health Services currently has a consensus price target of $77.81, indicating a potential upside of 9.27%. Hims & Hers Health has a consensus price target of $31.53, indicating a potential upside of 59.86%. Given Hims & Hers Health's higher possible upside, analysts clearly believe Hims & Hers Health is more favorable than BrightSpring Health Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BrightSpring Health Services
0 Sell rating(s)
0 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
3.11
Hims & Hers Health
1 Sell rating(s)
12 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13

BrightSpring Health Services has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.53, meaning that its stock price is 153% more volatile than the broader market.

In the previous week, Hims & Hers Health had 57 more articles in the media than BrightSpring Health Services. MarketBeat recorded 63 mentions for Hims & Hers Health and 6 mentions for BrightSpring Health Services. BrightSpring Health Services' average media sentiment score of 1.04 beat Hims & Hers Health's score of -0.30 indicating that BrightSpring Health Services is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BrightSpring Health Services
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Hims & Hers Health
2 Very Positive mention(s)
6 Positive mention(s)
22 Neutral mention(s)
25 Negative mention(s)
2 Very Negative mention(s)
Neutral

Summary

BrightSpring Health Services beats Hims & Hers Health on 11 of the 17 factors compared between the two stocks.

How does Hims & Hers Health compare to Tempus AI?

Tempus AI (NASDAQ:TEM) and Hims & Hers Health (NYSE:HIMS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

Tempus AI currently has a consensus target price of $79.37, suggesting a potential upside of 10.85%. Hims & Hers Health has a consensus target price of $31.53, suggesting a potential upside of 59.86%. Given Hims & Hers Health's higher probable upside, analysts clearly believe Hims & Hers Health is more favorable than Tempus AI.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tempus AI
1 Sell rating(s)
10 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.45
Hims & Hers Health
1 Sell rating(s)
12 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13

Hims & Hers Health has a net margin of -6.65% compared to Tempus AI's net margin of -12.54%. Hims & Hers Health's return on equity of -9.62% beat Tempus AI's return on equity.

Company Net Margins Return on Equity Return on Assets
Tempus AI-12.54% -47.00% -9.44%
Hims & Hers Health -6.65%-9.62%-1.38%

24.2% of Tempus AI shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 24.3% of Tempus AI shares are held by insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Hims & Hers Health has higher revenue and earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tempus AI$1.27B10.27-$245.03M-$1.06N/A
Hims & Hers Health$2.35B1.97$128.37M-$0.83N/A

Tempus AI has a beta of 3.61, suggesting that its stock price is 261% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.53, suggesting that its stock price is 153% more volatile than the broader market.

In the previous week, Hims & Hers Health had 48 more articles in the media than Tempus AI. MarketBeat recorded 63 mentions for Hims & Hers Health and 15 mentions for Tempus AI. Tempus AI's average media sentiment score of 0.65 beat Hims & Hers Health's score of -0.30 indicating that Tempus AI is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tempus AI
6 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Hims & Hers Health
2 Very Positive mention(s)
6 Positive mention(s)
22 Neutral mention(s)
25 Negative mention(s)
2 Very Negative mention(s)
Neutral

Summary

Hims & Hers Health beats Tempus AI on 10 of the 16 factors compared between the two stocks.

How does Hims & Hers Health compare to Fresenius Medical Care AG & Co. KGaA?

Hims & Hers Health (NYSE:HIMS) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hims & Hers Health$2.35B1.97$128.37M-$0.83N/A
Fresenius Medical Care AG & Co. KGaA$22.20B0.53$1.11B$1.7312.75

Hims & Hers Health has a beta of 2.53, meaning that its share price is 153% more volatile than the broader market. Comparatively, Fresenius Medical Care AG & Co. KGaA has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Fresenius Medical Care AG & Co. KGaA has a net margin of 4.23% compared to Hims & Hers Health's net margin of -6.65%. Fresenius Medical Care AG & Co. KGaA's return on equity of 9.08% beat Hims & Hers Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Hims & Hers Health-6.65% -9.62% -1.38%
Fresenius Medical Care AG & Co. KGaA 4.23%9.08%4.04%

Hims & Hers Health currently has a consensus price target of $31.53, suggesting a potential upside of 59.86%. Fresenius Medical Care AG & Co. KGaA has a consensus price target of $23.43, suggesting a potential upside of 6.16%. Given Hims & Hers Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Hims & Hers Health is more favorable than Fresenius Medical Care AG & Co. KGaA.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hims & Hers Health
1 Sell rating(s)
12 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13
Fresenius Medical Care AG & Co. KGaA
5 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.58

In the previous week, Hims & Hers Health had 55 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 63 mentions for Hims & Hers Health and 8 mentions for Fresenius Medical Care AG & Co. KGaA. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 0.92 beat Hims & Hers Health's score of -0.30 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hims & Hers Health
2 Very Positive mention(s)
6 Positive mention(s)
22 Neutral mention(s)
25 Negative mention(s)
2 Very Negative mention(s)
Neutral
Fresenius Medical Care AG & Co. KGaA
7 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 8.4% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Hims & Hers Health and Fresenius Medical Care AG & Co. KGaA tied by winning 8 of the 16 factors compared between the two stocks.

How does Hims & Hers Health compare to DaVita?

DaVita (NYSE:DVA) and Hims & Hers Health (NYSE:HIMS) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

DaVita has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.53, suggesting that its stock price is 153% more volatile than the broader market.

DaVita has a net margin of 6.49% compared to Hims & Hers Health's net margin of -6.65%. Hims & Hers Health's return on equity of -9.62% beat DaVita's return on equity.

Company Net Margins Return on Equity Return on Assets
DaVita6.49% -225.93% 5.42%
Hims & Hers Health -6.65%-9.62%-1.38%

90.1% of DaVita shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 1.9% of DaVita shares are owned by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Hims & Hers Health had 48 more articles in the media than DaVita. MarketBeat recorded 63 mentions for Hims & Hers Health and 15 mentions for DaVita. DaVita's average media sentiment score of 0.53 beat Hims & Hers Health's score of -0.30 indicating that DaVita is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DaVita
4 Very Positive mention(s)
1 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Hims & Hers Health
2 Very Positive mention(s)
6 Positive mention(s)
22 Neutral mention(s)
25 Negative mention(s)
2 Very Negative mention(s)
Neutral

DaVita has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than DaVita, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaVita$14.17B0.78$746.80M$13.5812.87
Hims & Hers Health$2.35B1.97$128.37M-$0.83N/A

DaVita presently has a consensus target price of $235.86, indicating a potential upside of 34.92%. Hims & Hers Health has a consensus target price of $31.53, indicating a potential upside of 59.86%. Given Hims & Hers Health's higher probable upside, analysts plainly believe Hims & Hers Health is more favorable than DaVita.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DaVita
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57
Hims & Hers Health
1 Sell rating(s)
12 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13

Summary

DaVita beats Hims & Hers Health on 10 of the 16 factors compared between the two stocks.

Get Hims & Hers Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HIMS vs. The Competition

MetricHims & Hers HealthHealthcare Providers & Services IndustryHealthcare SectorNYSE Exchange
Market Cap$4.60B$10.86B$7.89B$23.55B
Dividend YieldN/A2.54%2.47%3.78%
P/E Ratio-23.7736.2734.5929.83
Price / Sales1.602.118.643.28
Price / Cash23.5823.2821.0215.64
Price / Book8.293.994.804.11
Net Income$128.37M$335.01M$3.52B$1.08B
7 Day Performance-13.85%-2.55%-3.20%-1.58%
1 Month Performance-29.73%0.01%-1.47%0.28%
1 Year Performance-46.82%21.17%1.46%7.30%

Hims & Hers Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HIMS
Hims & Hers Health
2.8301 of 5 stars
$19.73
0.0%
$31.53
+59.9%
-46.8%$4.60B$2.87BN/A2,442
GH
Guardant Health
3.548 of 5 stars
$154.01
-8.6%
$191.00
+24.0%
+60.8%$20.64B$982.02MN/A2,506
BTSG
BrightSpring Health Services
3.6417 of 5 stars
$65.94
-5.5%
$77.81
+18.0%
+122.5%$13.11B$12.91B35.6023,500
TEM
Tempus AI
2.2989 of 5 stars
$69.92
-7.5%
$79.37
+13.5%
+4.6%$12.55B$1.27BN/A3,800
FMS
Fresenius Medical Care AG & Co. KGaA
3.5428 of 5 stars
$23.58
+1.7%
$23.43
-0.6%
-5.6%$12.54B$19.48B13.621,488

Related Companies and Tools


This page (NYSE:HIMS) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners